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Abstract
Background: Thrombin generation (TG) assays evaluate the balance between pro- 
and anticoagulant forces, to better assess bleeding and thrombotic risks. Although TG 
readouts obtained with the calibrated automated TG have been investigated in multi-
ple clinical conditions, TG still needs standardization and clinical validation. The auto-
mated TG instrument ST Genesia® (STG, Stago, Asnières-sur-Seine, France) provides 
a normalization of TG parameters based on a reference plasma aiming to reduce the 
interlaboratory variability and the variability between different measurement runs.
Objectives: To evaluate STG in a group of healthy adults.
Methods: Reference intervals in healthy adults and variability of the new standard-
ized reagents for bleeding (BleedScreen) and thrombophilic (ThromboScreen) condi-
tions were determined using STG.
Results: TG was measured in platelet-free plasma (PFP) samples of 123 healthy 
adults. Reference intervals were determined for TG parameters. Intra- and interassay 
coefficients of variation were calculated on quality controls and PFP samples from 
healthy adults. Oral contraception (OC) possibly influenced TG parameters, result-
ing in a higher median and a broader reference interval for peak height and endog-
enous thrombin potential (ETP) in women aged 20 to 49 years than in all other sex 
and age categories. Therefore, we propose the following reference interval catego-
ries: men, women aged <50 years not using OC, women aged <50 years using OC, 
and women aged ≥50 years. Normalization was effective to reduce the interassay 
variability of quality controls for ETP (BleedScreen assay), and peak height and ETP 
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1  | INTRODUCTION
Predicting the risk of bleeding and thromboembolic disorders re-
mains a major health issue. Through the formation of an insufficient 
or an exaggerated amount of thrombin, the dysfunctional coagula-
tion system is responsible for these pathologies. Therefore, several 
global coagulation assays have been developed during the past 
50 years to assess the overall coagulation potential. Among them, 
thrombin generation (TG) testing investigates TG itself and the en-
tire process of thrombin inhibition as a whole, to get insight into the 
complicated balance between pro- and anticoagulant forces and 
to identify potential hemostatic impairments.1‒4 In platelet-poor 
plasma (PPP), TG testing can detect all coagulation factor deficien-
cies except factor XIII deficiency.5‒7 It is sensitive to anticoagulant 
drugs8,9 and to procoagulant states such as deficiency in antithrom-
bin,10 protein C, or protein S11 as well as to hyperprothrombinemia12 
and resistance to activated protein C.13,14
The method of TG testing developed by Hemker et al,1,15 the so-
called calibrated automated thrombography (CAT) has been used and 
studied in numerous conditions during the past 15 years. The use of a 
calibrator allows an accurate measurement of the amount and activity 
of the generated thrombin. In addition, the detection of fluorescence 
allows the measurement in cellular milieu such as platelet-rich plasma.16
However, although numerous data have been published with 
CAT assay consistent with high added value for clinical practice, 
this methodology still misses standardization and clinical validation. 
This is due to the lack of a standard experimental protocol, reagents, 
and analyzer, responsible for a large interlaboratory variability, and 
to the absence of large clinical studies in which the treatment deci-
sion is based on TG testing results.17‒23 Recently, a larger study on 
lab-to-lab variability has been published showing an improvement by 
normalization of the data using a single reference plasma.24
Lately, a new TG analyzer (ST Genesia®, Stago) has been released 
as the first fully automated TG analyzer for clinical routine laboratories 
together with a set of reagents balanced for sensitivity to procoagu-
lant and anticoagulant protein deficiencies (https://www.stago.com/
products-services/new-products/detail/article/thrombin-generation-
now-available-in-laboratories/). In comparison to the CAT assay, ST 
Genesia® provides a normalization of each TG parameter based on a 
reference plasma for each test aiming to reduce the interlaboratory vari-
ability as well as the variability between different measurement runs 
(https ://www.stago.com/produ cts-servi ces/new-produ cts/detai l/ 
artic le/throm bin-gener ation -now-avail able-in-labor atori es/).
In the present study, the ST Genesia® Thrombin Generation 
System was evaluated in a healthy adult sample. Our intent was not 
only to test the inter- and intra-assay variability of the new analyzer 
and reagents but also to establish accurate normal reference inter-
vals for all TG parameters to provide a clear view on the interindi-
vidual TG variability. Furthermore, we investigated the effect of sex, 
age, and oral contraception (OC) on the different TG parameters and 
determined which plasma pro- and anticoagulant proteins influence 
TG parameters.
2  | METHODS
2.1 | Cohort sample, blood collection, and processing
Blood samples were collected from healthy adult individuals, aged 
20 to 80 years, current or former employees of the hospital or ac-
quaintances of the hospital employees or former employees. An ad-
vertisement for the study was posted on the hospital intranet and 
posters were placed in hospitals buildings. Demographic data as 
well as information on medication, OC consumption, and hormone 
replacement therapy (HRT) were obtained by a questionnaire and 
completed by an interview. Inclusion criteria were age 20 to 80 years 
and not known to suffer any significant illness, in particular, no car-
diovascular disease including thrombotic disorders (except arterial 
hypertension under therapy) or bleeding disorder, diabetes, can-
cer, or infectious disease. Exclusion criteria were age <20 years or 
>80 years, chronic medication except pantoprazole and medication 
for arterial hypertension or depression, and pregnancy. The eth-
ics committee at our institution approved the study, and written 
(ThromboScreen assay without thrombomodulin), but had little impact on PFP sample 
variability.
Conclusion: STG appears suitable for accurate measurement of TG in healthy adults.
K E Y W O R D S
blood coagulation factors, clinical laboratory tests, quality control, reference ranges, thrombin 
generation
Essentials
• ST Genesia® (STG) is a new automated instrument to measure thrombin generation (TG) parameters.
• Reference intervals were determined for TG parameters measured with STG in healthy adults.
• Oral contraception possibly influenced TG parameters.
• STG appears to be suitable for the accurate measurement of TG in healthy adults.
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informed consent was obtained from all participants. No subject was 
directed to fast before collection.
Venous blood was obtained through antecubital venipunc-
ture and collected into 3.2% sodium citrate (10 mL, S-Monovette, 
Sarstedt, Nümbrecht, Germany) using a 21-gauge needle 
(0.80 × 19 mm, Terumo Surflo Winged Infusion Set, Terumo, 
Spreitenbach, Switzerland). Samples for TG were processed by dou-
ble centrifugation according to the guidelines recommendation of 
the subcommittee of the Scientific and Standardization Committee 
of the ISTH.19 Briefly, whole blood samples (10 mL) were centrifuged 
at 2500 g for 15 minutes at room temperature and 3 mL of PPP was 
collected in the middle of the tube, thus avoiding the platelets at the 
top surface and those at the buffy coat. The collected plasma was 
recentrifuged at 2500 g for 15 minutes at room temperature, and 
2.7 mL of supernatant (platelet-free plasma [PFP]) was collected. For 
routine coagulation analysis, 10 mL of venous blood was centrifuged 
at 1500 g for 20 minutes at room temperature to obtain approx-
imately 4 mL of PPP. The resulting PPP was stored in aliquots at 
−80°C. All the samples were collected between January and May 
2018. Measurements were all completed at the end of May 2018.
2.2 | Thrombin generation assays
Thrombin generation measurements were performed with the ST 
Genesia® Thrombin Generation System (Stago, Asnières-sur-Seine, 
France). Two types of reagents were used: the STG®-BleedScreen 
(STG-BLS) and the STG®-ThromboScreen (STG-TS). TG with the 
STG-BLS assay was initiated by a mixture of procoagulant phospho-
lipids and low picomolar level of human tissue factor (TF), balanced 
for sensitivity to procoagulant factor deficiencies while minimizing 
contact activation. The assay contained 2 quality controls for low and 
normal TG potential, respectively, and a reference plasma for param-
eter normalization. TG with the STG-TS assay was initiated by a mix-
ture of procoagulant phospholipids and medium picomolar level of 
human TF in the presence or absence of thrombomodulin (TM), bal-
anced for sensitivity to deficiencies in natural anticoagulants, without 
interfering contact activation. The assay contained 3 quality controls 
for low, normal, and high TM resistance and a reference plasma for 
parameter normalization. In the presence of both reagents, TG was 
triggered by dispensing a fluorogenic substrate and CaCl2. For the 
entire study, the same lots of STG-BLS (Lot: 202639, RUO label) and 
STG-TS reagents (LOT number: 202640, RUO label) were used. The 
following parameters were measured: lag time, peak height, time to 
peak, endogenous thrombin potential (ETP), ETP inhibition, and ve-
locity index.
A comparison with CAT (Stago) was performed in a small sub-
group of samples (n = 12), using 2 experimental settings similar to 
STG-BLS and STG-TS conditions. Briefly, in the first setting, 74 μL of 
PFP was added to 20 μL of a mixture of 1 pmol/L TF and 4 μmol/L 
phospholipids (PPP Reagent LOW, Stago)25 and 6 μL of HN-buffer 
(HEPES 20 mmol/L, NaCl 140 mmol/L, pH 7.4 + 5 mg/mL bovine 
serum albumin [BSA]), in a 96-well round-bottom microtiter plate 
(Immulon2HB, Thermo Fisher Scientific, Reinach, Switzerland). For 
the second setting, 74 μL PFP was added to 20 μL of a mixture of 
5 pmol/L TF and 4 μmol/L phospolipids (PPP Reagent)25 and 6 μL 
of recombinant human TM (4 nmol/L, Sekisui Alveo AG, Lucern, 
Switzerland) or HN-buffer (HEPES 20 mmol/L, NaCl 140 mmol/L, 
pH 7.4 + 5 mg/mL BSA), in a 96-well round-bottom microtiter plate 
(Immulon2HB). The reaction was initiated with 20 μl of a mixture of 
fluorogenic substrate and CaCl2 (Fluobuffer, Stago) and fluorescence 
measured using a Fluoroskan Ascent reader (Thermo Labsystems). All 
experiments were carried out in duplicate at 37°C. Thrombin gener-
ation curves were generated using Thrombinoscope software, ver-
sion 5.0.0.742 (Thrombinoscope BV, Maastricht, The Netherlands). 
Lag time, peak height, time to peak, and ETP were calculated.
2.3 | Coagulation assays
Prothrombin time (Dade Innovin, Siemens Healthcare, Munich, 
Germany); activated partial thromboplastin time (APTT; SL Pathrombin, 
Siemens); fibrinogen (Clauss Method, Dade Thrombin, Siemens); an-
tithrombin (Innovance Antithrombin, Siemens); prothrombin; and fac-
tors V, VII, and X (FII, FVII, FV, and FX Deficient Plasmas, Siemens) 
were measured using a Sysmex CS-5100 coagulometer (Siemens). Free 
protein S (Free PS Ag Innovance, Siemens); protein C (chromogenic: 
Berichrom, Siemens; coagulant: PC Reagent, Siemens); activated pro-
tein C resistance (Coatest APC Resistance V, Endotell), and factors 
VIII, IX, and XI were determined using a BCS-XP analyzer (Siemens).
2.4 | Statistical analysis
Continuous variables were expressed as median and interquartile 
range (25%-75%). Interindividual variability (coefficient of variation 
[CV]) was calculated for each variable as 100 × (standard deviation/
mean). Normal reference intervals for STG-TGA parameters were 
calculated on normalized values by using nonparametric tests, in 
agreement with Clinical and Laboratory Standards Institute guide-
lines.26 The lower reference interval limit was estimated as the 
2.5th percentile and the upper limit as the 97.5th percentile of the 
TA B L E  1   Characteristics of the studied sample
Characteristic Men (n) Women (n)
Number 61 62
Age categories, y
20-49 34 31
50-80 27 31
Hormonal therapy
Oral contraceptiona — 8
Hormone replacement therapy — 5
Race/Ethnicity
Asian 1 (2%) 1 (1.5%)
Black 2 (3%) 1 (1.5%)
Caucasian 58 (95%) 60 (97%)
aTwenty-four percent of women aged 20-49 use hormonal 
contraception. 
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distribution. Data were checked for normality. Groups were com-
pared by using the Mann–Whitney U-test for independent samples 
and Tukey's multiple comparisons test. The Pearson correlation was 
calculated to verify the association between different parameters. 
Statistical analysis was performed using Prism 7 software (GraphPad 
Software, San Diego, CA).
3  | RESULTS
3.1 | Characteristics of the study group
Of 124 healthy adults aged 20 to 80, one was excluded because of 
pregnancy at week 13 of gestation, leaving a study sample of 123. 
Characteristics of the studied sample are listed in Table 1. Overall, 
61 subjects were men (49.6%) and the median age was 47 (interquar-
tile range [IQR], 24-80) for men and 49.5 (IQR 21-77) for women. 
All subjects, men and women, were almost equally distributed in 2 
age categories: 20 to 49 and 50 to 80. Ninety-five percent of the 
men and 92% of the women were Caucasian. Eight women took OC 
(24% of the women aged 20-49), indicating that, regarding OC, the 
studied sample is representative of the Swiss population, of which 
25% of the women aged 15 to 49 take OC.27 Five women used HRT 
(16% of the women aged 50 to 80). Twenty-four healthy adults took 
medication only once during the last 7 days before the blood draw: 
11 of them took nonsteroidal antirheumatic drugs (8 aged 20-49 and 
3 aged 50-80), 2 took aspirin (1 aged 20-49 and 1 aged 50-80), 1 
aged 20-49 took metamizole, 9 took acetaminophen (5 aged 20-49 
and 4 aged 50-80), and 1 took a painkiller (not otherwise specified). 
Several healthy adults were on the following medication: nono-
ral contraceptive (1 woman aged 20-49), pantoprazole (2 healthy 
adults), duloxetine,1 fluoxetine,1 blood pressure medication (6, 
mainly angiotensin-converting enzyme inhibitors; among them, 2 
were in the 20-49 age group and 4 were in the 50-80 age category).
Coagulation parameters, including pro- and anticoagulants, mea-
sured in the studied population are shown in Table S1. Some dif-
ferences were found between sexes (Table S1A). Men aged 20 to 
49 displayed lower fibrinogen and factor VIII levels, and higher free 
protein S levels than women belonging to the same age category. 
Men aged 50 to 80 had lower factor V and antithrombin levels but 
higher factor IX than women aged 50 to 80. Differences were also 
found between age categories of adults of the same sex (Table S1B). 
Women and men aged 50 to 80 displayed a shorter prothrombin 
time as well as higher levels of fibrinogen, factor V, factor VII, and 
factor IX than women and men aged 20 to 49. Factor XI, antithrom-
bin, protein C, and free protein S were higher in women aged 50 
to 80 than in women aged 20 to 49. Factor VIII was higher in men 
aged 50 to 80 than in men aged 20 to 49, whereas antithrombin level 
was higher in men aged 20 to 49 than in men aged 50 to 80. There 
were also differences regarding coagulation parameters between 
women using and not using OC (Table S2). Indeed, women taking 
OC displayed a shorter APTT as well as higher factors II, X, and IX. 
Although there was a trend for a lower free protein S level in women 
taking OC in comparison to women not taking OC, the difference 
was not statistically significant.
3.2 | Thrombin generation parameters measured by 
ST Genesia® using the STG‐BLS
Normalized peak height values are presented in Figure 1A and nor-
malized ETP values, in Figure 1B. Men aged 20 to 49 years showed 
significantly lower normalized peak height and ETP values than 
women belonging to the same age category (P < 0.0001). This dif-
ference might be possibly due to the consumption of OC by some 
of the women of this age group (P < 0.0001; Figure 1A, B). Indeed, 
there was no difference regarding the normalized peak height and 
ETP values between men aged 20 to 49 and women aged 20 to 49 
not taking OC (Figure 1A, B). Normalized peak height and ETP val-
ues, however, did not differ significantly in men and women aged 50 
to 80 (Figure 1A, B). In addition, both parameters statistically dif-
fered for women aged 20 to 49 and 50 to 80 (P < 0.0001). There was 
no difference between men aged 20 to 49 and 50 to 80. We then 
F I G U R E  1   ST Genesia BleedScreen parameters in the age 
categories 20-49 years and 50-80 years, respectively. (A) Peak 
height normalized. (B) Endogenous thrombin potential (ETP) 
normalized. Data from all men are shown by blue boxes. Data from 
all women are shown by pink boxes. Data from women aged 20-49 
are divided in 2 groups: women using oral contraception (green 
boxes) and women not using oral contraception (red boxes). Median 
and interquartile range are indicated. Groups were compared using 
the Mann-Whitney U-test. The dotted lines show the threshold 
proposed by Stago. ns, not significant; ****P < 0.0001
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established reference intervals for all thrombin generation param-
eters in all sex and age categories (Table 2). Based on these results, 
we propose to use the 4 following reference interval categories for 
the routine hemostasis laboratory: men, women aged <50 years not 
using OC, women aged <50 years using OC, and women ≥50 years 
(Table 2).
3.3 | Thrombin generation parameters measured by 
ST Genesia® using the STG‐TS
Normalized peak height and normalized ETP values obtained in 
the absence of TM are presented in Figure 2A and 2B, respec-
tively. Men aged 20 to 49 years showed significantly lower nor-
malized peak height and ETP values than women belonging to the 
same age category (P < 0.0001). This difference was possibly due 
to the OC consumption by some of the women of this age group 
(Figure 2A, B; P < 0.00). Indeed, there was no difference regard-
ing the normalized peak height and ETP values between men aged 
20 to 49 and women aged 20 to 49 not taking OC (Figure 2A, B). 
Normalized peak height and ETP values, however, did not differ 
significantly in men and women aged 50 to 80. However, these 2 
parameters statistically differed for women aged 20 to 49 and 50 
to 80 (P < 0.00; Figure 2A, B). There was a difference in normal-
ized peak height but not in normalized ETP between women aged 
20 to 49 not using OC and women aged 50 to 80 (Figure 2A, B). 
In presence of soluble TM, we observed a significantly higher ETP 
inhibition in men aged 20 to 49 years as compared to women be-
longing to the same age category (Figure 2C). This difference was 
possibly due to the consumption of OC by some of the women of 
this age group (Figure 2C). Indeed, there was no difference regard-
ing ETP inhibition between men aged 20 to 49 and women aged 
20 to 49 not using OC (Figure 2C). This difference might be due to 
OC consumption in the female group aged 20 to 49. ETP inhibition, 
however, did not differ significantly in men and women aged 50 to 
80. However, ETP inhibition differed for women aged 20 to 49 and 
50 to 80 (P < 0.0001; Figure 2C). We then established reference 
intervals for all thrombin generation parameters in all sex and age 
categories (Table 3). Based on these results, we propose for the rou-
tine laboratory to use the 4 following reference interval categories: 
men, women aged <50 years not using OC, women aged <50 years 
using OC, and women aged ≥50 years (Table 3).
3.4 | Correlation between hemostasis/thrombophilia 
parameters and thrombin generation parameters 
measured with ST Genesia®
Correlation (coefficients) of the linear regression model (r) and P val-
ues between hemostasis/thrombophilia parameters and thrombin 
generation parameters were calculated in the study group (Table S3).
In STG-BLS (low picomolar TF concentration), peak height and 
ETP values positively correlated with factors VIII and X, and neg-
atively with APTT, factor XI, antithrombin, and free protein S 
(Figure 3A). Protein C (both coagulant and chromogenic values) cor-
related negatively only with ETP.
In STG-TS (medium picomolar TF concentration), peak height pos-
itively correlated with factors VIII, IX, and X, while negative correla-
tions were found for APTT, factor V, antithrombin, and free protein 
S. ETP without TM positively correlated with factor VIII and nega-
tively with factor IX, antithrombin, and free protein S (Figure 3A).
STG-TS ET-inhibition parameters positively correlated with fac-
tors V, IX, and XI; antithrombin; protein C (both coagulant and chro-
mogenic); and free protein S (Figure 3B).
TA B L E  2   Interindividual variability and 
reference intervals of thrombin generation 
parameters measured by ST Genesia in 
healthy adults using the BleedScreen 
assay
Age  
categories 
(y)
Lag time 
normalized 
(ratio)
Peak  
normalized 
(%)
Time 
to peak 
normalized 
(ratio)
ETP  
normalized 
(%)
Velocity 
index  
normalized 
(%)
Men
20-49 1.1 (1.0-1.2) 56 (41-61) 1.1 (1.0-1.2) 62 (49-74) 56 (44-71)
50-80 1.2 (1.1-1.4) 61 (43-82) 1.1 (1.1-1.3) 66 (51-92) 58 (42-90)
All men 
(20-80)
1.1 (1.0-1.3) 57 (42-72) 1.1 (1.0-1.2) 64 (51-79) 58 (44-76)
Women
20-49 1.0 (0.9-1.1) 85 (71-114) 1.0 (0.9-1.0) 84 (70-99) 95 (73-141)
50-80 1.2 (1.0-1.3) 48 (40-67) 1.2 (1.0-1.3) 57 (48-74) 47 (35-67)
Women
20-49 
using OC
1.0 (0.9-1.0) 143 (115-202) 0.9 (0.8-1.0) 123 (103-145) 174 (144-322)
20-49 not 
using OC
1.0 (0.9-1.1) 78 (59-88) 1.0 (0.9-1.1) 78 (65-90) 82 (68-105)
Data are expressed as median and interquartile range (25th-75th percentile). ETP, endogenous 
thrombin potential; OC, oral contraception.
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3.5 | Inter‐ and intra‐assay variability of thrombin 
generation parameters measured by ST Genesia®
We calculated the interassay variability of ST Genesia® quality con-
trols (QCs) and reference plasma for both STG-BLS and STG-TS (with 
and without TM) assays (Tables S4 and S5). For the STG-BLS assay 
(n = 33 tests), the CVs of all the absolute and normalized STG param-
eters (lag time, peak, time to peak, ETP, velocity index) ranged be-
tween 2.1% and 13% for the QCs (Table S4) and between 2.6% and 
13%, for the reference plasma (Table S5). Similarly, for the STG-TS 
without TM assay (n = 45 tests), the CVs of STG parameters ranged 
between 2% and 12% for all the QCs (Table S4) and reference plasma 
(Table S5). For the TS with TM assay (n = 45 tests), the CVs of STG 
parameters ranged between 2.0% and 13%.
Moreover, we calculated the inter- and intra-assay variability of 
the TG parameters measured by the ST Genesia system in 4 healthy 
adults (n = 4; 2 men and 2 women) to evaluate the intraindividual 
variability of BLS and TS assays on frozen PFP samples (Tables 4, 5, 
S6, and S7).
For the interassay variation (Tables 4 and S6), each healthy adult 
frozen PFP sample was measured 5 times in the 5 independent assays 
(different calibration curve and QCs/reference plasma check). For the 
BLS assay, the range of the CVs of all absolute and normalized STG 
parameters was large to very large for all 4 healthy adults (healthy adult 
1, 0.2%-14%; healthy adult 2, 3.6%-17%; healthy adult 3, 3.8%-21%; 
healthy adult 4, 2.3%-34%). For the TS without TM assay, the CVs of 
all absolute and normalized STG parameters ranged between 1.6% and 
10% for healthy adult 1, between 2.2% and 8% for healthy adult 2, be-
tween 1.9% and 8% for healthy adult 3, and between 1.9% and 11% for 
healthy adult 4. For the TS with TM assay, the CVs of STG parameters 
and ETP inhibition ranged between 2.1% and 15% for healthy adult 1, 
between 3.2% and 9% for healthy adult 2, between 5.0% and 13% for 
healthy adult 3, and between 1.6% and 13% for healthy adult 4.
For the intra-assay variability (Tables 5 and S7), each healthy 
adult frozen PFP sample was measured 5 times in the same assay 
(same calibration curve and QCs/reference plasma check). For the 
BLS assay, the CVs of all the absolute and normalized STG parame-
ters (lag time, peak, time to peak, ETP, start tail, and velocity index) 
ranged between 1.3% and 10% for healthy adult 1, between 2.3% 
and 12% for healthy adult 2, between 1.9% and 15% for healthy 
adult 3, and between 0.7% and 11% for healthy adult 4. For the 
TS without TM assay, the CVs of all absolute and normalized STG 
parameters ranged between 1.6% and 12% for donor 1, between 
1.1% and 7.5% for healthy adult 2, between 2.9% and 12% for 
healthy adult 3, and between 1.1% and 13% for healthy adult 4. 
For the TS with TM assay, the CVs of STG parameters and ETP 
inhibition ranged between 1.8% and 14% for healthy adult 1, 
between 0.8% and 7.9% for healthy adult 2, between 5.1% and 
13% for healthy adult 3, and between 2.0% and 4.9% for healthy 
adult 4.
3.6 | Correlation between ST Genesia® Thrombin 
Generation Measurement System and CAT assay
TG parameters measured by ST Genesia® and by CAT in a subset 
of the studied population (n = 12) are provided in Table S8. We cal-
culated the correlation between peak height and ETP parameters 
(absolute values) measured by ST Genesia and those determined by 
F I G U R E  2   ST Genesia ThromboScreen parameters in the 
age categories 20-49 and 50-80, respectively. (A) Peak height 
normalized. (B) Endogenous thrombin potential (ETP) obtained 
in absence of thrombomodulin normalized. (C) Endogenous 
thrombin potential (ETP) obtained in presence of thrombomodulin 
normalized. Data from all men are shown by blue boxes. Data 
from all women are shown by pink boxes. Data from women aged 
20-49 are divided in 2 groups: women using oral contraception 
(green boxes) and women not using oral contraception (red boxes). 
Medians and interquartile ranges are indicated. Groups were 
compared using the Mann-Whitney U-test. The dotted lines show 
the threshold proposed by STAGO. TM, thrombomodulin; ns, not 
significant; **P < 0.01; ***P < 0.001; ****P < 0.0001
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the CAT assay. Peak height and the ETP showed a positive correla-
tion between the STG-BLS and PPP Reagent LOW assays (r, 0.75 and 
r, 0.62; P < 0.001, respectively).
Peak height but not ETP measured in the absence of TM cor-
related between STG-TS and PPP Reagent (r, 0.84, P < 0.00, and 
0.28, P = 0.07, respectively). In presence of TM, the ETP and the 
ETP inhibition correlated in STG-TS and PPP Reagent assays (r, 0.70, 
P = 0.00; and 0.85, P < 0.00, respectively).
4  | DISCUSSION
We report the first study to date on TG measured by the automated ST 
Genesia® STG in a group of 123 healthy adults. STG is a new automated 
instrument to measure TG parameters. Reference intervals were deter-
mined for TG parameters measured with STG in healthy adults. We re-
port here that OC possibly influenced TG parameters,1 and STG appears 
to be suitable for the accurate measurement of TG in healthy adults.2
As previously reported, we found differences in the levels of 
some coagulation factors and inhibitors between sex and age cate-
gories. In addition, women aged 20 to 49 using OC displayed a higher 
level of some coagulation factors and a trend for a lower free pro-
tein S level than women of the same age category who did not take 
OC. These results are consistent with previous publications.28‒32
The investigation of the interindividual variability allowed us to 
define 4 different categories of reference interval for ST Genesia® 
TG parameters: men, women aged <50 years not using OC, women 
aged <50 years using OC, and women aged ≥50 years. The rationale 
for the establishment of these categories was the possible influence 
of OC on TG parameters, resulting in a higher median and a broader 
reference interval for peak height and ETP in women aged 20 to 
49 years than in all other sex and age categories.
The most important determinants of the amount of throm-
bin formed, as quantified by peak height and/or ETP, were, for both 
BleedScreen and ThromboScreen assays, factor VIII, antithrombin, and 
free protein S. As expected, proteins C and S were determinants of the 
effect of TM. In the presence of medium picomolar concentration of TF 
and TM, the inhibition of the ETP was remarkably affected by factor IX 
and XI levels. Interestingly, fibrinogen as well as factor V and VII levels 
were not, in our study group, found to be relevant. There was no cor-
relation between resistance to activated protein C and TG parameters 
in the studied population. Because previous studies demonstrated an 
increase of TG in subjects with APC resistance,13,14 we did not expect, 
in the study group, to find no correlation between TG parameters and 
resistance to APC. However, this could be explained by the fact that 
none of the included healthy adults displayed APC resistance (Table S1).
Normalization was effective to reduce the inter-assay variabil-
ity of QCs for ETP (BleedScreen assay), and peak height and ETP 
(ThromboScreen assay without TM). As already reported,24 the ve-
locity was the most variable parameter, the CVs being the highest of 
the series, and some of the values being even worse after normal-
ization. For the ThromboScreen assay with TM, the values were not 
normalized and higher CVs were calculated (up to 13%).
Inter- and intra-assay variability of normal plasma samples re-
vealed very high CVs for the velocity index, even after normaliza-
tion, particularly when measured with BleedScreen and for healthy 
adults 3 and 4. High CVs for the velocity index, the most variable TG 
parameter, were previously reported.24 In addition, the interassay 
variability study revealed extremely high CVs for the absolute peak 
height and ETP values when measured with the BleedScreen assay 
for healthy adults 3 and 4. Normalization had no or only little impact 
on variability. These results are in line with previous observations, 
indicating that variability of TG parameters remains important and 
is not always reduced by normalization.24 However, normalization 
TA B L E  3   Interindividual variability and reference intervals of thrombin generation parameters measured by ST Genesia in healthy adults 
using the ThromboScreen assay
Age categories 
(y)
Lag time  
normalized (ratio)
Peak normalized 
(%)
Time to peak  
normalized (ratio)
ETP  
normalized (%)
Velocity index 
normalized (%)
ETP  
inhibition (%)
Men
20-49 1.1 (1.1-1.3) 54 (46-60) 1.2 (1.1-1.4) 69 (59-82) 46 (34-54) 66 (58-71)
50-80 1.3 (1.2-1.3) 58 (45-69) 1.2 (1.2-1.3) 67 (59-78) 52 (37-62) 69 (60-73)
All men (20-80) 1.2 (1.1-1.3) 55 (45-66) 1.2 (1.2-1.3) 68 (59-80) 49 (36-57) 67 (60-73)
Women
20-49 1.0 (1.0-1.1) 76 (64-102) 1.1 (1.0-1.2) 82 (73-99) 69 (54-112) 58 (47-67)
50-80 1.3 (1.1-1.4) 49 (40-63) 1.4 (1.2-1.5) 66 (58-74) 40 (31-50) 72 (62-76)
Women
20-49 not 
using OC
1.1 (1.0-1.1) 66 (58-76) 1.2 (1.0-1.2) 76 (70-82) 61 (53-77) 61 (55-68)
20-49 using 
OC
0.9 (0.9-1.1) 118 (103-139) 0.9 (0.8-1.1) 101 (95-111) 149 (95-214) 33 (21-48)
Data are expressed as median and interquartile range (25th-75th percentile). Normalized lag time, peak, time to peak, and ETP values have been ob-
tained using ThromboScreen assay in the absence of thrombomodulin. The ETP inhibition parameter has been calculated from ETP values obtained in 
presence and in absence of thrombomodulin. ETP, endogenous thrombin potential; OC, oral contraception.
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might be useful to reduce lab-to-lab variability the ST Genesia® sys-
tem,24 but this needs to be investigated.
Finally, we were able to show that TG parameters measured 
with ST Genesia® correlated well with most of the comparable 
parameters measured with the CAT assay. The exception is the 
ETP without TM (ThromboScreen) measurement that did not cor-
relate with ETP obtained with the CAT assay with 5 pM TF. We are 
unable to comment on this result, as the concentration of TF and 
F I G U R E  3   Correlations between some 
hemostasis/thrombophilia parameters 
and ETP values in the study group. (A) 
ETP was measured using the BleedScreen 
assay and the ThromboScreen assay. 
(B) Endogenous thrombin potential 
(ETP) inhibition was measured using the 
ThromboScreen (TS) assay in presence/
absence of thrombomodulin. AT, 
antithrombin; ETP, endogenous thrombin 
potential; FIX, factor IX; free PS, free 
protein S; FV, factor V; FVIII, factor VIII; 
PC:c, protein C coagulant; r, Pearson 
coefficient; STG-BLS, BleedScreen; 
STG-TS, ThromboScreen
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phospholipids used for the ST Genesia® ThromboScreen assay was 
not disclosed by Stago.
Our study has some limitations. First, the study included only 
123 participants from a single center, with samples analyzed in 1 
laboratory. Second, the study comprised a small number of healthy 
adults. Thus, confirmation on a larger cohort would be required, and 
a multicenter study would certainly be the most appropriate design. 
Third, only 1 batch of reagents was used for this study. Therefore, it 
would be necessary to verify that different batches of reagents do 
not affect the validity of the results. Previous data obtained with 
CAT showed that changes of reagent batches did not impact the re-
sults.25 However, this was not tested with the ST Genesia®. Fourth, 
the studied sample was mainly Caucasian, being representative of 
the Swiss population. Thus, it is indeed unclear whether the re-
sults of this study can be extrapolated to other race/ethnic groups. 
Additional studies should be undertaken to investigate whether the 
same range can be used for all race/ethnic groups. Fifth, we did not 
study within-person variability. This is a gap that will need to be filled 
by future studies. Sixth, we do not provide data on freeze-thaw ef-
fects. Future studies will have to comprise these data.
In conclusion, the ST Genesia® Thrombin Generation System 
with BleedScreen and ThromboScreen assays appears to be suitable 
for the accurate measurement of TG parameters in healthy adults. 
However, this study was not performed to demonstrate the clinical 
utility of this system. Future studies will comprise pathologic sam-
ples to determine how this system can be used in the management 
TA B L E  4   Peak and ETP interassay variability in normal frozen platelet-free plasma samples for BleedScreen and ThromboScreen assays
ST Genesia 
(STG) assay STG parameter Value
Healthy adult 1 
Mean ± SD, CV (%)
Healthy adult 2 
Mean ± SD, CV (%)
Healthy adult 3 
Mean ± SD, CV (%)
Healthy adult 4 
Mean ± SD, CV (%)
BleedScreen Peak Absolute (nmol/L) 174 ± 20, 12 114 ± 16, 14 94 ± 18, 19 87 ± 23, 27
Normalized (%) 130 ± 13, 9.7 85 ± 11, 13 70 ± 13, 19 64 ± 17, 26
ETP Absolute 
(nmol/L × min)
1099 ± 100, 9.1 953 ± 125, 13 677 ± 113, 17 699 ± 134, 19
Normalized (%) 110 ± 9, 8.1 95 ± 11, 12 68 ± 12, 17 70 ± 13, 19
ThromboScreen 
without TM
Peak Absolute (nmol/L) 235 ± 15, 6.4 177 ± 11, 6.3 169 ± 12, 6.9 148 ± 14, 9.6
Normalized (%) 90 ± 8, 8.7 68 ± 5, 7.1 64 ± 5, 7.0 56 ± 5, 9.5
ETP Absolute 
(nmol/L × min)
1140 ± 512, 4.5 1138 ± 48, 4.2 958 ± 48, 5.1 937 ± 45, 4.8
Normalized (%) 83 ± 4, 5.3 83 ± 4, 4.9 69 ± 4, 6.2 67 ± 4, 6.0
ThromboScreen 
with TM
Peak Absolute (nmol/L) 152 ± 21, 14 83 ± 7, 8.9 93 ±  9, 9.4 95 ± 12, 13
ETP Absolute 
(nmol/L × min)
574 ± 81, 14 346 ± 31, 8.9 349 ± 29, 8.3 408 ± 52, 13
ETP inhibition Ratio (%) 50 ±  6, 12 70 ± 2, 3.2 65 ± 5, 7.2 56 ± 5, 8.9
Data are expressed as mean and standard deviation (SD). CV, coefficient of variation; ETP, endogenous thrombin potential; TM, thrombomodulin.
TA B L E  5   Peak and ETP intra-assay variability in normal frozen platelet-free plasma samples for BleedScreen and ThromboScreen assays
ST Genesia 
(STG) assay STG parameter Value
Healthy adult 1 
Mean ± SD, CV (%)
Healthy adult 2 
Mean ± SD, CV (%)
Healthy adult 3 
Mean ± SD, CV (%)
Healthy adult 4 
Mean ± SD, CV (%)
BleedScreen Peak Absolute (nmol/L) 157 ± 8.5, 5.5 105 ± 11, 10 109 ± 15, 14 117 ± 8.6, 7.4
Normalized (%) 127 ± 6.9, 5.4 77 ± 7.8, 10 87 ± 12, 14 93 ± 6.9, 7.4
ETP Absolute 
(nmol/L × min)
1029 ± 37, 3.6 865 ± 61, 7.0 805 ± 106, 13 960 ± 57, 5.9
Normalized (%) 109 ± 3.9, 3.5 88 ± 6.1, 7.0 84 ± 11, 13 100 ± 6.0, 5.9
ThromboScreen 
without TM
Peak Absolute (nmol/L) 218 ± 11, 4.9 173 ± 6.4, 3.7 157 ± 16, 9.8 136 ± 4.6, 3.4
Normalized (%) 85 ± 4.1, 4.9 65 ± 2.4, 3.7 60 ± 5.9, 9.8 51 ± 1.7, 3.4
ETP Absolute 
(nmol/L × min)
1086 ± 41, 3.7 1102 ± 34, 3.1 908 ± 58, 6.4 889 ± 22, 2.4
Normalized (%) 81 ± 3.0, 3.7 79 ± 2.4, 3.1 64 ± 4.1, 6.4 62 ± 1.5, 2.4
ThromboScreen 
with TM
Peak Absolute (nmol/L) 134 ± 16, 12 73 ± 3.2, 4.3 87 ± 8.2, 9.5 94 ± 2.9, 3.1
ETP Absolute 
(nmol/L × min)
512 ± 64, 13 3032 ± 10, 3.3 330 ± 26, 7.9 406 ± 13, 3.1
ETP inhibition Ratio (%) 52 ± 6.1, 13 73 ± 0.9, 1.2 64 ± 1.5, 2.4 54 ± 1.3, 2.3
Data are expressed as mean and standard deviation (SD). CV, coefficient of variation; ETP, endogenous thrombin potential; TM, thrombomodulin.
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of patients with bleeding or thrombotic disorders. The DrugScreen 
assay still has to be evaluated. Finally, it will also be important to 
assess the external quality, as it was performed for the CAT assay.24
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